Growth hormone shows no benefit to ALS in Phase III
This article was originally published in Scrip
Executive Summary
A growth hormone, insulin-like growth factor-1 (IGF-1), previously thought to show promise in treating amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), has been ruled out as a possible therapy by a Phase III trial led by the US organisation, Mayo Clinic, the journal Neurology reported.